FIGURE 8.

GW6471 decreased fatty acid uptake and fatty liver in PPARA‐humanized mice. (A–C) The anti‐NAFLD effect of GW6471 in PPARA‐humanized mice and Ppara ^−/− mice, n = 5. (A) H&E (scale bar, 50 µm) and Oil Red O staining (scale bar 100 µm). (B) Liver weight, TG, and TC (upper) and serum ALT, TG, and TC (bottom) (n = 5). (C) Western blot analyses of intestinal FABP1 protein. (D,E) Intestinal organoids isolated from PPARA‐humanized mice were treated with WY14643 (100 µM) or together with GW6471 (6 µM) for 24 h. (D) Western blot analyses of FABP1 protein. (E) BODIPY‐C₁₂ and NBD‐stearate uptake in organoids (n = 3) and representative immunofluorescence images; scale bar, 100 µm. (F) A schematic diagram depicting the role of intestinal PPARα‐FABP1 axis in NASH progression. *p < 0.05, **p < 0.01, ***p < 0.001. WY, WY14643. GW, GW6471